Hormone-resistant prostate carcinoma
MONDO:0056814Prostate carcinoma that does not respond to hormone therapy.
Also known as: hormone-resistant prostate cancer, hormone-resistant prostate carcinoma
2771 clinical trials for this condition and its sub-types, 30 tagged with Hormone-resistant prostate carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Can a Chemo-Radio duo slow advanced prostate cancer?
Disease control Stopped earlyThis trial is testing whether combining the chemotherapy drug docetaxel with a radioactive agent called samarium can help men with advanced prostate cancer that has stopped responding to hormone therapy. Participants are men aged 18 to 80 who have bone metastases and whose diseas…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Experimental combo for tough prostate cancer shows early promise but trial halted
Disease control Stopped earlyThis study tested a combination of two drugs, bortezomib and docetaxel, in 15 men with advanced prostate cancer that had stopped responding to hormone therapy. The goal was to see if the combo could lower PSA levels and ease pain. The trial was terminated early, so the findings a…
Phase 2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental drug targets Hard-to-Treat cancers, but trial ends early
Disease control Stopped earlyThis study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminat…
Phase 2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo treatment targets returned prostate cancer
Disease control Stopped earlyThis study tested a treatment for prostate cancer that came back after previous radiation. It combined temporary radioactive implants placed in the prostate, daily external radiation to the pelvis for 5 weeks, and 6 months of hormone therapy. The goal was to see if this approach …
Phase 1/2 • Sponsor: Loyola University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC